#SitC17 - Twitter Hashtag

over 7 years ago

The $FPRX mini disaster has been brewing for some time, at least since the #SITC17 clusterfuck. I guess few believed these #JPM19 claims

Jacob Plieth @JacobPlieth

almost 8 years ago

You do the math, $FPRX tells #JPM19

2

12

2

0

2

5

0

2

0

Bursatil Biotech

@BursatilBiotech

over 8 years ago

Right at the beginning of this year, $NKTR jumped 20% over unreleased data. They have only said they have expanded their cohort from #SITC17 . More time needed? https://t.co/nCbMfW3FJx

Bursatil Biotech

@BursatilBiotech

over 8 years ago

Yes, we know. Biotech has a lot of cash so as to either acquire COs or get rights. But who set these prices? $BMY $NKTR Data can be compelling but where is the "prove, build, scale" concept going? (im having a hard time trying to forget about that concept @LifeSciVC jaja )

2

5

1

0

2

0

Bertrand Delsuc @BertrandBio

over 8 years ago

yet another proof of improved CD8+ T cell infiltration in the TME leveraging the CXCR4/CXCL12 axis. Previous similar data at #SITC17 from X4 Pharma. Relevant for Noxxon $ALNOX who should have similar data in H1. Looking forward to combo data w/ anti-PD-1 #turncoldintohot https://t.co/XITQIx4rue

Odi Bruckman @odibro

over 8 years ago

$BLRX Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer. Top line data 2H 2018 https://t.co/pjz1ef2GFG

1

2

0

1

5

4

0

Brad Loncar

@bradloncar

over 8 years ago

$NKTR is up more than $7 billion since #SITC17.

4

6

1

0

Bursatil Biotech

@BursatilBiotech

almost 9 years ago

@DrPaulyDeSantis Let me see if i get this clear U're saying that $NKTR expanded the cohort from #SITC17 until now,they havent released the data BUT they said (not show)data was,overall,impressive. So my q is: How can we know that the share price is worth +20% if we have nothing but just words?

3

0

Dr. Paul De Santis, PharmD

@DrPaulyDeSantis

almost 9 years ago

$NKTR " Our spider plot not really a spider plot anymore with NKTR-214, more like a limp squid plot...all responses at #SITC17 are now confirmed responses...:

0

7

2

0

EdisonHealthcare @EdisonHealth

almost 9 years ago

.@Primabio changes name to @Immutep. Presents encouraging LAG-3 combo data at #SITC17 https://t.co/pi4h0V8Yds $IMM

0

1

2

0

Dr. Paul De Santis, PharmD

@DrPaulyDeSantis

almost 9 years ago

@ablT315I Sweet keep me posted. Key tidbit from #SITC17 from Mackall was “dont target reversing exhaustion markers, target restoring polyfunctionality” seems intuitive/obvious but very insightful because reversing markers does not necessarily lead to polyfunctionality

0

1

0

linhdtu @tuduylinh

almost 9 years ago

@Jdalexander64 well vol is high w $tril bec float is low. if #ASH17 tox data on high dose of .2 to .5 is tolerable and there is sign of drug activity , it will go much higher. #SITC17 showed #TTI-621 is active, if dosage can be higher then we have a real drug

0

1

0

Dr. Paul De Santis, PharmD

@DrPaulyDeSantis

almost 9 years ago

@gulleyj1 Move them in and remove the break, I enjoyed all the oncolytic virus stuff at #SITC17 this yr, starting to really warm up to the modality.

1

0

Dr. Paul De Santis, PharmD

@DrPaulyDeSantis

almost 9 years ago

@Biomaven Probably one of the most significant things I saw at #SITC17 too actually. TRIL and Shattuck lab poster presenters disussing the approach. TRIL PI had no pushback and was very interested in their approach

1

2

0

The Angeles Clinic @angelesclinic

almost 9 years ago

As promised @immunocore @sitcancer #SITC17 #melsm #ocularmelanoma data - fascinating ... @MRFCureOM @AIMatMelanoma @CureMelanoma @MelanomaReAlli https://t.co/oWDuYtcz6F

0

2

0

Omid Hamid MD

@OmidHamidMD

almost 9 years ago

As promised @immunocore @sitcancer #SITC17 #melsm #ocularmelanoma data - fascinating ... @MRFCureOM @AIMatMelanoma @CureMelanoma @MelanomaReAlli https://t.co/adC4NJ7mdp

0

16

5

0

ASGCT

@ASGCTherapy

almost 9 years ago

#CART #CellTherapy for prostate cancer eliminated cancer in two-thirds of mice that received treatment in research presented at #SITC17. https://t.co/hw8iNNTnCy

1

0

Jack Allen @JohnK_Allen

almost 9 years ago

In your opinion which IDO inhibitor shows the most promise? Please vote and RT to expand sample size Comment with opinions supporting your choice $NLNK $BMY $INCY $MRK $XBI $IBB #SITC17

1

0

Evaluate Pharma @evaluatepharma

almost 9 years ago

#SITC17 Oncosec heats up tumours, and so might competition https://t.co/6HHrtbYyfM via @JacobPlieth @EdwinElmhirst @EPVantage

evaluatepharma's tweet photo. #SITC17 Oncosec heats up tumours, and so might competition https://t.co/6HHrtbYyfM via @JacobPlieth @EdwinElmhirst @EPVantage https://t.co/jD8BH4seH4

1

2

0

Andy Biotech

@AndyBiotech

almost 9 years ago

Timely paper on CSF1R for some new idea on this target after $FPRX $ARRY data at #SITC17 Does CSF1R Blockade Turn into Friendly Fire? https://t.co/H2SRQT1aIB https://t.co/Hl3n9q9zo1

AndyBiotech's tweet photo. Timely paper on CSF1R for some new idea on this target after $FPRX $ARRY data at #SITC17

Does CSF1R Blockade Turn into Friendly Fire?
https://t.co/H2SRQT1aIB
https://t.co/Hl3n9q9zo1 https://t.co/F2842yebwP

3

9

4

1

0

Omid Hamid MD

@OmidHamidMD

almost 9 years ago

@Immunocore #melanoma #ocular #uveal @sitcancer #SITC17 poster here. @cure_magazine @MRFCureOM @AIMatMelanoma @MelanomaReAlli

0

7

0

BIOTECH @_B_I_O_T_E_C_H_

almost 9 years ago

#SITC17 early + rapid expansion of $JUNO JCAR015 "was certainly associated with fatal cerebral edema" “off-the-shelf" product offers the unique ability to be dosed adaptively ie. start therapy on very low doses especially in patients with the highest tumorburden $SGMO #allogeneic

1

3

1

0

BIOTECH @_B_I_O_T_E_C_H_

almost 9 years ago

#SITC17 Key Opinion Leader Dr. Stephan Grupp emphasized the positive arguments for an “#off_shelfproduct" as “no waiting period for treatment" and "less expensive" Further, Dr. Grupp confirmed that an #allogeneic CAR T would be highly disruptive to autologous CAR Ts. $SGMO $CLLS

1

9

7

0

Top Tweets for #SitC17

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users